Objective Few studies have examined microalbuminuria (MAU) in non-western populations. We assessed the prevalence of MAU in the general population of a middleincome country in the African region and relationships between MAU and selected cardiovascular risk factors.
Introduction
Microalbuminuria (MAU) is defined as an increased urine albumin excretion (30-300 mg per 24 h) that is undetectable by standard protein dipstick testing [1] . MAU has been recognized as an early sign of renal damage and a predictor of end-stage renal disease in diabetic patients [2, 3] . In addition, MAU is recognized as a predictor of cardiovascular morbidity and mortality, even in the absence of diabetes or overt impaired kidney function [4] [5] [6] [7] . These relationships of MAU with both renal function and cardiovascular risk suggest that screening for MAU is a useful additional test for identifying persons at risk for developing renal and cardiovascular complications [8] .
A limitation in defining a universal role of MAU as a tool for surveillance or screening is the paucity of both prevalence and outcome data in several populations. In particular, the prevalence of MAU is largely unknown in non-western populations [9] and we are not aware of any population-based survey in the African region.
The gold standard for MAU measurement is based on 24-h urine collection [1] . Alternatively, MAU can be assessed using nontimed random spot urine sampling [10] . Spot sample-based tests are generally adjusted to creatininuria to take into account the variation in urinary flow rate and concentration and the test is considered positive for the albumin/creatinine ratio (ACR) of 30-300 mg albumin/g creatinine, corresponding to 3.4-33.9 mg albumin/mmol creatinine [11, 12] . ACR can be measured either quantitatively or semiquantitatively. Semiquantitative ACR, which can be done using a point-of-care analyzer and fairly inexpensive reagents, The aim of this study was to estimate the prevalence of MAU using semiquantitative spot urine sampling in the general population of the Seychelles, a rapidly developing country in the African region, and to investigate the relationship between MAU and selected cardiovascular risk factors in this population.
Methods
The Republic of Seychelles is a group of islands in the Indian Ocean situated 2000 km east of Kenya. Although intermarriage has blurred racial differences in many inhabitants, it can be considered that approximately two-thirds of the population are of predominantly African descent, 15% are of white, Indian or Chinese descent and a fifth are mixed between these various groups. The national gross domestic product per capita, in real terms, increased from US$2927 in 1980 to US$5239 in 2004, reflecting booming tourism and industrial fishing industries. Increased levels of cardiovascular risk factors, particularly overweight, hypertension and diabetes, have been documented in the adult population in 1989 and 2004 [14, 15] .
In 2004, a population-based survey of cardiovascular risk factors was conducted (Seychelles Heart Study III). The methods of the survey have been reported previously [15] . Briefly, a random sex-stratified and age-stratified sample of all inhabitants aged 25-64 years was drawn using computerized data of a national population census carried out in 2002 and thereafter regularly updated by civil status authorities. Eligible persons were invited by letter to join one of the study centers. The survey was approved by the Ministry of Health. Persons were free to participate and gave written informed consent.
Weight and height were measured and body mass index (BMI) was calculated. Blood pressure (BP) was measured several times in persons seated for at least 30 min, using a cuff adjusted to the arm circumference. We used the average of the second and third measurement, obtained with a mercury sphygmomanometer. BP categories followed usual recommendations [16] .
Venous blood was drawn in the morning after an overnight fast. All samples were centrifuged within 2 h of blood collection and plasma was immediately frozen to À208C. Blood sugar was measured using a Cholestec pointof-care analyzer. If the value was at least 5.6 mmol/l, an additional capillary measurement -adjusted for plasma values -was carried out (Ascencia Elite glucometer; Bayer, Leverkussen, Germany) and the average of the two readings was considered. An oral glucose tolerance test was performed if the fasting blood glucose concentration was at least 5.6 mmol/l and less than 7 mmol/l and with no reported history of diabetes [17] . Other analyses were performed in the Laboratory of the Kantonspital, St Gallen (Switzerland) and included creatinine, cystatin C, high-density lipoprotein cholesterol (HDL-c) and triglycerides. Low-density lipoprotein cholesterol (LDL-c) was calculated with the Friedewald formula. The Modification of Diet in Renal Disease-formula (4v-MDRD) was used to estimate the creatinine clearance [18] . Stages of chronic kidney disease (CKD) were classified along the K/DOQI guidelines [19] .
Microalbuminuria was measured with a Clinitek Status analyzer (Bayer) on a spot of the second morning urine (0800-1100 h) after an overnight fast. We used the second morning urine instead of the first morning urine for practical reasons as participants had to be examined in a few study centers and travel accordingly (most often by bus, travel duration of <1 h in most cases). This analyzer uses a sulphonephthalein dye binding to measure albumin and the peroxidase-like activity of copper creatinine complexes to measure creatinine. The color yields of the separate reaction pads are monitored by a reflectance photometer and compared with a preprogrammed calibration algorithm [20] . Thus, it provides four categories of albumin concentration (10, 30, 80 and 150 mg/l) and five categories of creatinine concentration (0.9, 4.4, 8.8, 17.7 and 26.5 mmol/l), as well as three calculated categories of ACR: normal albuminuria (< 3.4 mg albumin/mmol creatinine), microalbuminuria (3.4-33.9 mg albumin/mmol creatinine) and macroalbuminuria (> 33.9 mg albumin/mmol creatinine).
These categories are based on an in-built preprogrammed calculation by the device that cannot be modified and on the -preprogrammed -classic definition of MAU (3.4-33.9 mg albumin/mmol creatinine).
The distribution of cardiovascular risk factors (mean values and prevalence) was standardized for age using the new World Health Organization standard population [21] . Differences in age-standardized estimates were tested using Student's t-test for continuous variables and x 2 -test for categorical variables. We examined the univariate and multivariate relationships between microalbuminuria and other cardiovascular risk factors and other markers of renal function using logistic regression analysis, appropriately weighted for the stratified study design. All P-values were two-sided and values less than 0.05 were considered significant. Analyses were performed using SPSS software version 14.0 (SPSS Inc., Chicago, Illinois, USA).
Results
Of the 1563 eligible persons, 1255 participated in the survey, a participation rate of 80.2%. This study refers to 1218 participants after exclusion of 25 persons reporting menstruations or acute urinary tract infections and 12 persons with incomplete data. The prevalence of CKD stages 3-5 was low in participants in this survey [19] . No participant had CKD stage 5; CKD stage 4 was found in 0.3% of participants aged 55-64 years, CKD stage 3 was found in 7.1% of participants aged 55-64 years; overall, 3.2% of participants had CKD stages 3-4.
The prevalence of MAU according to sex and age is shown in Table 1 . Overall, the prevalence of MAU increased from 3.8% at age 25-34 years to 23.6% at age 55-64 years. The prevalence of MAU was slightly higher in women than in men, irrespective of age. Examined separately, albuminuria increased over age categories whereas creatininuria did not. A total of 87.3% of subjects had urine creatinine values of 8.8 mmol/l or higher. This suggests that most subjects had rather concentrated urine. Table 2 shows the prevalence of MAU by categories of sex, age, high blood pressure (HBP) and diabetes, stratified by age and sex. Estimates for age 25-64 years are standardized for age. The patterns of prevalence of MAU across categories of HBP and diabetes were largely similar in men and in women. Overall (men and women aged 25-65 years), the prevalence of MAU increased largely across categories of BP (respectively 7 vs. 24% in persons with less or more than 140/90 mmHg, P < 0.01) and categories of blood glucose (respectively 8 vs. 36% in persons with or without diabetes, P < 0.01). Note that prevalence of MAU among persons with 'hypertension' (first four rows in Table 2 ) is in contrast to persons 'without hypertension'; hence, these persons may or may not also have diabetes. The same remark applies for categories of diabetes (rows 5-7 in Table 2 ) and these persons may or may not also have hypertension. The prevalence of MAU increased gradually across categories of normal BP, hypertension stage 1 and hypertension stage 2 (respectively 7, 18 and 34%; P < 0.01 for all differences). Similarly, the prevalence of MAU increased gradually across categories of normal blood glucose, impaired glucose tolerance and diabetes (respectively 8, 17 and 36%; P < 0.01 for all differences). The prevalence of MAU was low among persons of all ages without diabetes or HBP (5%), as compared with 20% in persons Prevalence of microalbuminuria in Seychelles Pruijm et al. 873 Standard error is given within parentheses. Prevalence for categories 25-64 years is standardized for age. Participants with macroalbuminuria were excluded from this analysis. IGT, impaired glucose tolerance.
with either hypertension or diabetes and 41% in persons with both hypertension and diabetes (P < 0.001 for all differences). ), hypertension and diabetes remained associated with MAU. Analyses conducted separately in men and in women showed largely similar patterns of associations, except for an association with obesity in women [odds ratio (OR) 3.0; 95% confidence interval (CI) 1.4-6.4] but not in men (0.69; 95% CI: 0.29-1.63) and a trend toward a stronger association with hypertension and diabetes in men than in women.
Multivariate OR shown in Table 3 relating diabetes and hypertension to MAU remained virtually identical upon further adjustment for renal function markers (creatinine, cystatin C and 4v-MDRD) alone or in combination (data not shown). For example, the OR for diabetes was 3.02 (2.83-3.23) without adjustment for renal markers and 2.91 (2.71-3.12) with adjustment for creatinine, cystatin C and 4v-MDRD. This indicates that the relationships between MAU and hypertension and diabetes are largely independent of renal function markers.
Discussion
Taken together, the results of this analysis show a high prevalence of microalbuminuria in the general adult population of Seychelles, a strong association between microalbuminuria and hypertension and diabetes and that these associations are independent of renal function markers.
We are not aware of any previous large-scale, populationbased estimate of the prevalence of MAU in the African region. The prevalence of MAU at age 25-64 years (11.4%) was high in the population of Seychelles as compared with the population-based data of western countries. The prevalence of MAU in predominantly white populations ranged between 6 and 11.6% (Table 4 [22] [23] [24] [25] [26] [27] [28] ) and was approximately 7% in African Americans aged more than 6 years [29, 30] . Compared with white individuals, African individuals tend to have higher muscle mass, hence higher urine creatinine excretion and lower rates of creatinine-adjusted MAU [31] . This systematic difference would tend to underestimate the prevalence of MAU in Seychelles as compared with the studies in white individuals [31] .
Several factors underlie the high prevalence of MAU in our study. First, the prevalence of hypertension (e.g. 32% with BP !140/90 mmHg at age 25-64 years) and diabetes (11% at age 25-64 years) is high in the Seychelles by International Standards [15] . Approximately, one-third (36.1%) of persons with diabetes had MAU and this percentage increased further (to 41.6%) in the presence of associated hypertension, underlining the additional effect of these conditions on MAU. Second, the prevalence of obesity is also high in Seychelles (e.g. 25% at age 25-64 years). Excess body weight has been reported to be associated with MAU and albuminuria independently of other risk factors such as hypertension and diabetes Participants with macroalbuminuria were excluded from this analysis. Prevalence is standardized for age. CI, confidence interval; FBG, fasting blood glucose; HDL, highdensity lipoprotein; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; LDL, low-density lipoprotein; OR, odds ratio; 2hG, glucose 2 h after 75 g glucose meal. a Standard error is given within parentheses.
[22]. The high prevalence of MAU in the population of Seychelles illustrates the changing epidemiological situation related to the rapid emergence of noncommunicable diseases in countries in health transition and the subsequent new challenges for healthcare systems [32] .
The prevalence of MAU was slightly higher in women than in men in our study, whereas the reverse was found in several other populations [33] [34] [35] . Increased prevalence of MAU in women than in men might be related to lower muscle mass -hence creatininuria -in women. Therefore, some authors [23] [24] [25] have suggested the use of sex-related cut-off values to define MAU (2.5-30 mg/ mmol for men and 3.5-30 mg/mmol for women). There is however, so far, no definite consensus and some current recommendations advise for sex-specific cut-offs [24, 25, 36] whereas others do not [26, 27] . Furthermore, the semiquantitative method used in this study has not been developed to provide sex-specific results. Using a sex-specific threshold, however, might result in a MAU prevalence moderately higher in men and lower in women as compared with the current results, but the overall MAU prevalence might not be altered substantially. Such sex-specific criteria might have a particular impact on the prevalence of MAU in the youngest age category in which muscle mass -hence urinary creatinine excretion -is high. Although the increased prevalence of MAU in women than in men in our study may relate, in part, to the chosen cut offs, this difference is also consistent with a markedly increased prevalence of overweight in women than in men in Seychelles [15] , as obesity has been found to be an independent risk factor of MAU.
The strong associations between MAU and both hypertension and diabetes in the Seychelles are consistent with findings in other populations [28, 34, 35, 37, 38] . The mechanisms underlying these relationships are still debated.
There is increasing evidence for a causal pathway linking diabetes, hypertension and the metabolic syndrome to systemic (including glomerular) endothelial dysfunction [39] , increased vessel wall permeability and leakage of lipoproteins and albumin (including MAU) and, finally, accelerated atherosclerosis [40] . These mechanisms might also explain the higher cardiovascular mortality found in persons with MAU [5] .
The relationships between MAU and hypertension and diabetes remained largely unchanged upon adjustment for markers of renal function such as creatinine, 4v-MDRD and cystatin C in our study. This finding is consistent with the hypothesis that MAU is the consequence of systemic dysfunction (e.g. endothelial dysfunction) rather than the sole consequence of renal impairment. This is also consistent with the evidence that the presence of MAU independently increases cardiovascular risk in persons with diabetes and/or hypertension [7, 33, 34] . In the Framingham study [6] , MAU was shown to independently increase the cardiovascular risk by three-fold. The crosssectional design of our study, however, precludes firm conclusions on causality.
The use of a semiquantitative method for MAU screening in our study is another limitation. This can be a source of some misclassification but we do not expect a systematic bias in the overall prevalence estimate. Other studies [1, 13, 15, 41] have used semiquantitative devices as they correlate well with quantitative methods, as shown, for example, by a sensitivity of 75-85% and a specificity of 85-94% when compared with the latter.
Our study raises the question of the potential usefulness of MAU screening for identifying persons at increased risk of cardiovascular and/or renal complications in populations experiencing epidemiological transition.
Prevalence of microalbuminuria in Seychelles Pruijm et al. 875 Table 4 Review of large studies that have reported the prevalence of microalbuminuria in the general population MAU screening is attractive and possibly cost-effective [42] as it is technically easy to perform (e.g. spot urine, inexpensive reagents and no need for the intervention of a specialist) and it gives information on both cardiovascular and renal risk [43] .
Nevertheless, several issues deserve attention. First, it is not established whether persons with isolated MAU should receive treatment [e.g. angiotensin-converting enzyme (ACE) inhibitor] although some recent studies [8, 44] (in western countries) showed a reduction in cardiovascular events and urinary albumin excretion in persons treated with an ACE inhibitor as primary prevention. Second, screening strategies need more clarification: which individuals should be screened (e.g. in terms of associated risk factors or absolute risk stratification) and how MAU should be assessed (e.g. albuminuria vs. ACR, modalities for urine collection, need for confirmatory test if a first test is positive). Third, more data are needed to show that MAU screening would improve treatment as compared with therapeutic decisions based on medical information other than MAU (e.g. medical history, physical examination, risk factors and so on). On that note, MAU could also constitute a tool for health education and studies could examine whether patients aware of MAU would be, for example, more motivated to adhere to treatment (e.g. lifestyle changes, medication for hypertension or diabetes). Fourth, more studies are needed to expand our knowledge on the prevalence of MAU in different populations and the relationship between MAU and cardiovascular and renal outcomes in these populations. In a context of low resource settings, and given that MAU determination is noninvasive and relatively inexpensive (e.g. US$2-3 per test), MAU could serve as a simple means for assessing an individual's cardiovascular risk, and perhaps particularly when risk stratification cannot rely on more invasive tests, including blood lipids.
In conclusion, our study provides the first estimate of the prevalence of MAU in an African population in health transition. By showing strong associations between MAU and cardiovascular risk factors, our findings suggest that MAU could be a useful marker of cardiovascular risk to help identify patients in need of intensified cardiovascular risk management. Further prevalence and outcome studies in different populations are needed to further guide consensus on the value of MAU as a screening tool for renal and/or cardiovascular diseases.
